Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data DOI Open Access
Pierluigi Puca,

Angelo Del Gaudio,

Jacopo Iaccarino

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 735 - 735

Published: Feb. 21, 2025

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD). These agents offer advantage oral administration have demonstrated efficacy in inducing maintaining remission. However, concerns regarding their safety emerged, particularly concerning cardiovascular infectious complications, which appear more pronounced pre-existing risk factors such as older age, smoking, or comorbidities. While these risks are better understood, potential association between JAK inhibitors malignancies remains a subject ongoing investigation. Current data from randomised controlled trials, pooled integrated analyses, real-world studies provide conflicting evidence cancer risk. Notably, rheumatologic diseases treated contributed additional insights into long-term outcomes. Despite uncertainty surrounding malignancy risks, it is likely that predisposing factors, smoking history, long-standing IBD chronic inflammation, play substantial role development than inhibitor therapy alone. This paper reviews clinical meta-analyses, observational studies, focusing on IBD. We also review rheumatology highlighting need individualised assessment close monitoring to optimise profile medications practice.

Language: Английский

Chick Early Amniotic Fluid Alleviates Dextran-Sulfate-Sodium-Induced Colitis in Mice via T-Cell Receptor Pathway DOI Creative Commons
Fan Chen, Yining Zhao, Yanfa Dai

et al.

Antioxidants, Journal Year: 2025, Volume and Issue: 14(1), P. 51 - 51

Published: Jan. 4, 2025

Ulcerative colitis (UC) is a chronic immune disease that difficult to cure. We recently found chick early amniotic fluid (ceAF) has notable anti-inflammatory and antioxidative properties, through its active components. This study demonstrates the potential of ceAF as protective agent against UC. UPLC-MS mass spectrometry identified key components ceAF, including various fatty acids nucleosides. In vitro, improved viability in DSS-induced Caco-2 cells, reduced pro-inflammatory cytokines IL-1β TNF-α, increased cytokine IL-10. It also upregulated tight junction proteins ZO-1 occludin. UC mice, treatment alleviated weight loss, colon shortening, activity, while improving histopathology, crypt depth, colonic fibrosis. Mechanistically, ceAF's effects are mediated by inhibiting overactivation TCR signaling LCK/ZAP70/LAT pathway. Our findings suggest could be valuable nutritional intervention for UC, potentially enhancing existing functional foods aimed at managing this condition.

Language: Английский

Citations

1
An Analysis of the Effectiveness and Safety of Upadacitinib in the Treatment of Inflammatory Bowel Disease: A Multicenter Real-World Study DOI Creative Commons
Hongzhen Wu,

Tingting Xie,

Qiao Yu

et al.

Biomedicines, Journal Year: 2025, Volume and Issue: 13(1), P. 190 - 190

Published: Jan. 14, 2025

Background and Aims: Inflammatory bowel disease (IBD) requires effective treatment options. Upadacitinib, a Janus kinase 1 (JAK1) inhibitor, has shown effectiveness in trials for Crohn’s (CD) ulcerative colitis (UC). This study evaluates its real-world safety. Methods: We conducted multicenter retrospective cohort tertiary care centers, involving patients treated with upadacitinib from January 2023 to September 2024. The included adult aged 18 years or older, diagnosed UC CD, who received at least 8 weeks of therapy. Treatment outcomes were evaluated using established clinical, endoscopic, imaging, histological, laboratory parameters. Results: A total 236 IBD treatment. In 80 weeks, 64.0% achieved steroid-free remission, 57.6% clinical 81.8% response. Endoscopic remission was 35.8% (p = 0.039), 63.3% response mucosal healing. Histological reached 29.2% 0.009). For 156 CD 12 76.8% < 0.001), 77.8% 81.0% Mean CDAI decreased 214.9 117.5 0.001). 19.4%, 48.9% 4.9% Radiological 9.1% 85.7% Intestinal ultrasound showed 5.7% 56.7% Conclusions: Upadacitinib demonstrates significant safety IBD, particularly biologic-resistant cases, as evidenced by high rates These are likely due targeted JAK1 inhibition, which effectively reduces inflammation promotes Future research should focus on long-term safety, comparative other biologics, application diverse patient populations. findings support the integration into management strategies.

Language: Английский

Citations

0
Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders DOI
Azhagu Madhavan Sivalingam

Clinical Reviews in Allergy & Immunology, Journal Year: 2025, Volume and Issue: 68(1)

Published: Feb. 11, 2025

Language: Английский

Citations

0
Cancer Risk in IBD Patients Treated with JAK Inhibitors: Reassuring Evidence from Trials and Real-World Data DOI Open Access
Pierluigi Puca,

Angelo Del Gaudio,

Jacopo Iaccarino

et al.

Cancers, Journal Year: 2025, Volume and Issue: 17(5), P. 735 - 735

Published: Feb. 21, 2025

The advent of Janus kinase (JAK) inhibitors, including tofacitinib, filgotinib, and upadacitinib, has significantly widened the therapeutic options for patients with inflammatory bowel disease (IBD). These agents offer advantage oral administration have demonstrated efficacy in inducing maintaining remission. However, concerns regarding their safety emerged, particularly concerning cardiovascular infectious complications, which appear more pronounced pre-existing risk factors such as older age, smoking, or comorbidities. While these risks are better understood, potential association between JAK inhibitors malignancies remains a subject ongoing investigation. Current data from randomised controlled trials, pooled integrated analyses, real-world studies provide conflicting evidence cancer risk. Notably, rheumatologic diseases treated contributed additional insights into long-term outcomes. Despite uncertainty surrounding malignancy risks, it is likely that predisposing factors, smoking history, long-standing IBD chronic inflammation, play substantial role development than inhibitor therapy alone. This paper reviews clinical meta-analyses, observational studies, focusing on IBD. We also review rheumatology highlighting need individualised assessment close monitoring to optimise profile medications practice.

Language: Английский

Citations

0